The Global Health Body Issues Concern Over Severe Scarcity of Obesity Medications

Less than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the WHO as it publishes its inaugural guidance on the medications.

Given more than one billion individuals worldwide currently obese, it is advocating for more widespread and fairer availability to GLP-1 medication.

Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.

"The new guidelines affirms that obesity is a chronic disease that can be managed with holistic and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are key obstacles to universal availability to the jabs that can aid individuals in losing significant body mass, says the organization.

GLP-1 Therapy Supply Crisis

Even in the present most favorable outlook, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the WHO.

The guideline urges countries and companies to expand access, by strategies such as voluntary licensing.

A patent on the active ingredient – the core component of a leading brand – is set to lapse in several nations in 2026.

The Way Weight-Loss Drugs Function

GLP-1 drugs imitate a biological compound to slow digestion, suppress the appetite and enhance feelings of fullness so people reduce food intake.

Patients usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.

Research suggests patients may see weight return a year later of stopping the treatment, because their usual hunger resume.

To be carrying excess weight increases your risk for developing diseases, such as type 2 diabetes, heart disease, brain attack, and specific cancers.

Obesity impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.